Overview of the Downgrade#
BofA Securities has downgraded Inspire Medical Systems (NYSE: INSP) from a 'Buy' rating to 'Neutral' on Monday. The firm has significantly lowered its price target from $120 to $53, while the stock is currently trading at $54.84, reflecting a 65% decline over the past year.
Reasons for the Downgrade#
Analyst Travis Steed pointed to several challenges affecting Inspire Medical's growth, including uncertainty around reimbursement, coding issues, and increased competition in the market. The downgrade indicates a reduced long-term growth outlook for the company. According to data, Inspire Medical's net income is expected to decrease this year, with earnings per share (EPS) projected at $2.08 for 2026, down from $4.89 in the past twelve months.
Valuation Changes#
BofA has adjusted its valuation of Inspire Medical, now estimating the stock at 1.5 times the projected sales for 2026, a significant decrease from the previous multiple of 3.0 times. The analyst noted that the company's path to recovery and growth has become increasingly challenging.
Positive Aspects and Future Outlook#
Despite the downgrade, BofA acknowledged the quality of Inspire Medical's products, which maintain a strong gross profit margin of 85%, and the company's overall financial health, rated as 'GREAT' by InvestingPro. There are scenarios where reimbursement issues and other challenges could improve. Additionally, despite recent earnings that exceeded expectations, Mizuho has also lowered its price target for Inspire Medical from $70 to $55, citing a revised sales growth forecast that now anticipates a decline of 4% to 10% for 2026. This reflects the company's recent performance and adjusted future expectations.